Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Aug 12, 2025 · 10-Q · 43 days after period end · 0001731122-25-001105
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$13.24M | -$12.21M | -$11.28M | -$12.37M |
| EPS Diluted | -$0.16 | -$0.14 | -$0.14 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end
